Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis
dc.contributor.author | Meltzer, Eli | |
dc.contributor.author | Ratner, Paul | |
dc.contributor.author | Bachert, Claus | |
dc.contributor.author | Carr, Warner | |
dc.contributor.author | Berger, William | |
dc.contributor.author | Canonica, G. Walter | |
dc.contributor.author | Hadley, James | |
dc.contributor.author | Lieberman, Phil | |
dc.contributor.author | Hampel, Frank C. | |
dc.contributor.author | Mullol, Joaquim | |
dc.contributor.author | Munzel, Ullrich | |
dc.contributor.author | Price, David | |
dc.contributor.author | Scadding, Glenis | |
dc.contributor.author | Virchow, J. Christian | |
dc.contributor.author | Wahn, Ulrich | |
dc.contributor.author | Murray, Ruth | |
dc.contributor.author | Bousquet, Jean | |
dc.date.accessioned | 2020-06-16T10:45:01Z | |
dc.date.available | 2020-06-16T10:45:01Z | |
dc.date.issued | 2013-07 | |
dc.identifier.citation | Meltzer , E , Ratner , P , Bachert , C , Carr , W , Berger , W , Canonica , G W , Hadley , J , Lieberman , P , Hampel , F C , Mullol , J , Munzel , U , Price , D , Scadding , G , Virchow , J C , Wahn , U , Murray , R & Bousquet , J 2013 , ' Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis ' , International Archives of Allergy and Immunology , vol. 161 , no. 4 , pp. 369-377 . https://doi.org/10.1159/000351404 | en |
dc.identifier.issn | 1018-2438 | |
dc.identifier.other | PURE: 171119739 | |
dc.identifier.other | PURE UUID: b032e894-32e6-4db5-918f-9e59dd7eb949 | |
dc.identifier.other | Scopus: 84877679580 | |
dc.identifier.uri | https://hdl.handle.net/2164/14506 | |
dc.description | Acknowledgements This study was funded by MedaPharma. | en |
dc.format.extent | 9 | |
dc.language.iso | eng | |
dc.relation.ispartof | International Archives of Allergy and Immunology | en |
dc.rights | © 2013 S. Karger AG, Basel. This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercialNoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online version of the article only. Distribution for non-commercial purposes only https://creativecommons.org/licenses/by-nc-nd/4.0/ | en |
dc.subject | Allergic rhinitis | en |
dc.subject | Azelastine | en |
dc.subject | Fluticasone | en |
dc.subject | MP29-02 | en |
dc.subject | Responder analysis | en |
dc.subject | Severe chronic upper airway disease | en |
dc.subject | R Medicine (General) | en |
dc.subject.lcc | R1 | en |
dc.title | Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis | en |
dc.type | Journal article | en |
dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
dc.description.status | Peer reviewed | en |
dc.description.version | Publisher PDF | en |
dc.identifier.doi | https://doi.org/10.1159/000351404 | |
dc.identifier.vol | 161 | en |
dc.identifier.iss | 4 | en |